An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors.

Trial Profile

An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Letrozole; Oxaliplatin; Paclitaxel; Trastuzumab
  • Indications Breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 31 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 27 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top